Clinical Trials Browser

Phase 2 × Alzheimer Disease × Clear all

NCT04270175 2026-02-27

Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab

Phase 2 Active not recruiting

15 enrolled

Plasma cell

Immunoglobulin Light-chain Amyloidosis, Alzheimer Disease

NCT05522387 2026-02-27

An Open-Label Extension of XPro1595 in Patients With Alzheimer's Disease

Phase 2 Terminated

11 enrolled

CNS

Alzheimer Disease, Mental Disorders, Brain Diseases, Central Nervous System Diseases, Dementia, Inflammation, Nervous System Diseases, Neurodegenerative Diseases, Neurocognitive Disorders, Tauopathies

NCT06723015 2025-11-18

Tau PET Outcomes With Anti-amyloid Immunotherapies

Phase 2 Enrolling by invitation

135 enrolled

Lymphoid

Alzheimer Disease, Dementia, Lymphoma, Follicular, Cognitive Dysfunction

NCT05321498 2023-09-28

Study to Assess the Efficacy of XPro1595 in Patients With Mild Cognitive Impairment With Biomarkers of Inflammation

Phase 2 Withdrawn

CNS

Alzheimer Disease, Mental Disorders, Brain Diseases, Central Nervous System Diseases, Dementia, Inflammation, Nervous System Diseases, Neurodegenerative Diseases, Tauopathies, Cognitive Dysfunction

NCT01083316 2020-09-25

Bortezomib and Dexamethasone Followed by High-Dose Melphalan and Stem Cell Transplantation for Primary (AL) Amyloidosis

Phase 2 Completed

35 enrolled 9 charts

Plasma cell

Immunoglobulin Light-chain Amyloidosis, Alzheimer Disease, Amyloidosis

NCT02632786 2019-04-05

PRONTO

Phase 2 Completed

129 enrolled 18 charts

Plasma cell

Immunoglobulin Light-chain Amyloidosis, Alzheimer Disease, Amyloidosis, Paraproteinemias